Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib
[SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients
with metastatic renal cell carcinoma (Phase 1). To assess antitumor activity of the
combination of gefitinib and sunitinib (Phase 2).